Viral vector vaccine and gene therapies are a rapidly growing and evolving field. These products have a wide range of potential applications, such as treatment of cancer, genetic disorders and infectious disease. As with recombinant proteins, contamination with endogenous or adventitious virus is a concern in these cell culture driven processes. Potential sources of virus contamination are either endogenous related - such as process related / helper viruses, the use of contaminated cells banks, infected donors or other raw materials - or exogenous in nature such as contamination through manufacturing operators . Virus clearance is not a codified requirement for many GT viral vector products but may be expected by the Regulatory agencies depending on the type of product and applicability of clearance technologies. Patient safety is also improved by implementing virus clearance/inactivation steps in the process where possible, such as viral barrier technologies for upstream cell culture . As many of these advanced therapies have significantly limited downstream purifications, viral clearance capabilities that have been normalized in recombinant protein processes are no longer attainable in most cases. To address the concern regarding the possibility of contamination arising from raw materials, a virus clearance filter (Virosart Media) has been evaluated with 6 different medias used in viral vector manufacturing These medias have been specifically designed to support rapid cell growth and productivity, without the use of serum or hydrolyzates. These medias are chem. defined, animal-free, Protein-free, and available for research or manufacturing use. The Virosart Media filter has been specifically designed to provide robust clearance of virus >20 nm, with high flux rates, high capacities at an economical cost. The data presented in this poster suggests that the addition of a virus removal filtration step is a feasible and economical way to mitigate the risk of virus contamination and improve safety to patients.